ImpediMed Limited
Research ImpediMed Limited (IPD.AX) on Bullrun: market cap AUD 21.98M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIPD.AX
- ExchangeAU
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyAUD
- Market capAUD 21.98M
- Financial periodFY2026
- RevenueAUD 14.61M
- Revenue growth14.8%
- Net income-AUD 24.91M
- Free cash flow-AUD 19.13M
- Gross margin87.4%
Valuation Snapshot
latest market cap is AUD 21.98M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | AUD 14.61M | -AUD 24.91M | -AUD 19.13M | 87.4% | -0.01 | AUD 15.29M | AUD 16.60M | AUD 10.19M |
| FY2025 | AUD 12.72M | -AUD 23.24M | -AUD 15.63M | 86.3% | -0.01 | AUD 22.18M | AUD 14.49M | AUD 20.50M |
| FY2024 | AUD 10.05M | -AUD 19.79M | -AUD 20.89M | 86.9% | -0.01 | AUD 24.63M | AUD 1.14M | AUD 40.74M |
| FY2023 | AUD 11.25M | -AUD 20.52M | -AUD 24.09M | 86.3% | -0.01 | AUD 45.71M | AUD 1.45M | AUD 60.88M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-17 | AUD 21.98M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About ImpediMed Limited
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ImpediMed Limited's market cap?
ImpediMed Limited's market capitalization is AUD 21.98M.
What does ImpediMed Limited do?
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure.